Immunoprecise Antibodies Profit Margin vs. Market Capitalization

IPA
 Stock
  

USD 3.95  0.06  1.54%   

For Immunoprecise Antibodies profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunoprecise Antibodies to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunoprecise Antibodies utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunoprecise Antibodies's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunoprecise Antibodies over time as well as its relative position and ranking within its peers. Please see Risk vs Return Analysis.
  
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Immunoprecise Antibodies Market Capitalization vs. Profit Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Immunoprecise Antibodies's current stock value. Our valuation model uses many indicators to compare Immunoprecise Antibodies value to that of its competitors to determine the firm's financial worth.
Immunoprecise Antibodies is currently regarded as number one stock in profit margin category among related companies. It is currently regarded as number one stock in market capitalization category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Immunoprecise Antibodies by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Immunoprecise Antibodies' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunoprecise Antibodies' earnings, one of the primary drivers of an investment's value.

Immunoprecise Market Capitalization vs. Profit Margin

Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Immunoprecise Antibodies 
Profit Margin 
 = 
Net Income 
Revenue 
X
100 
(86.29) %
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Immunoprecise Antibodies 
Market Cap 
 = 
Shares Outstanding 
X  
Share Price 
77.72 M
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.

Immunoprecise Market Capitalization vs Competition

Immunoprecise Antibodies is currently regarded as number one stock in market capitalization category among related companies. Market capitalization of Biotechnology industry is currently estimated at about 155.44 Million. Immunoprecise Antibodies totals roughly 77.72 Million in market capitalization claiming about 50% of stocks in Biotechnology industry.
Capitalization  Revenue  Valuation  Workforce  Total debt

Immunoprecise Antibodies Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Immunoprecise Antibodies, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunoprecise Antibodies will eventually generate negative long term returns. The profitability progress is the general direction of Immunoprecise Antibodies' change in net profit over the period of time. It can combine multiple indicators of Immunoprecise Antibodies, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies is traded on NASDAQ Exchange in the United States.

Immunoprecise Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Immunoprecise Antibodies. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunoprecise Antibodies position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunoprecise Antibodies' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Immunoprecise Antibodies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio File Import Now

   

Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module

Use Investing Themes to Complement your Immunoprecise Antibodies position

In addition to having Immunoprecise Antibodies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 34 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
View All  Next Launch
Please see Risk vs Return Analysis. You can also try Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
To fully project Immunoprecise Antibodies' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Immunoprecise Antibodies at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Immunoprecise Antibodies' income statement, its balance sheet, and the statement of cash flows.
Potential Immunoprecise Antibodies investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Immunoprecise Antibodies investors may work on each financial statement separately, they are all related. The changes in Immunoprecise Antibodies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Immunoprecise Antibodies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.